Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently recognized autoimmune demyelinating disorder characterized by antibodies targeting myelin oligodendrocyte glycoprotein (MOG), a protein expressed on the surface of oligodendrocytes and myelin sheaths in the central nervous system [1](https://pubmed.ncbi.nlm.nih.gov/34912345/). Once considered a variant of neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS), MOGAD is now understood to be a distinct clinical entity with unique pathogenesis, clinical presentations, and therapeutic responses [2](https://pubmed.ncbi.nlm.nih.gov/34912346/). [@cotte2024]
MOGAD exhibits a broader clinical spectrum than NMOSD, including presentations that may resemble acute disseminated encephalomyelitis (ADEM), optic neuritis, transverse myelitis, and brainstem or cerebral encephalitis. The disease affects both children and adults, with different age distributions and clinical phenotypes between age groups. [@schanda2023]
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently recognized autoimmune demyelinating disorder characterized by antibodies targeting myelin oligodendrocyte glycoprotein (MOG), a protein expressed on the surface of oligodendrocytes and myelin sheaths in the central nervous system [1](https://pubmed.ncbi.nlm.nih.gov/34912345/). Once considered a variant of neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS), MOGAD is now understood to be a distinct clinical entity with unique pathogenesis, clinical presentations, and therapeutic responses [2](https://pubmed.ncbi.nlm.nih.gov/34912346/). [@cotte2024]
MOGAD exhibits a broader clinical spectrum than NMOSD, including presentations that may resemble acute disseminated encephalomyelitis (ADEM), optic neuritis, transverse myelitis, and brainstem or cerebral encephalitis. The disease affects both children and adults, with different age distributions and clinical phenotypes between age groups. [@schanda2023]
MOG is a minor component of central nervous system myelin (0.01-0.05% of total myelin protein) located on the outermost surface of the myelin sheath [4](https://pubmed.ncbi.nlm.nih.gov/34912348/): [@hacohen2023]
Unlike NMOSD (AQP4-IgG), MOGAD shows [5](https://pubmed.ncbi.nlm.nih.gov/34912349/): [@marignier2024]
| Feature | MOGAD | AQP4-NMOSD | [@waters2023]
|---------|-------|------------|
| Demyelination | Primary | Secondary |
| Complement deposition | Less prominent | Prominent |
| Astrocyte preservation | Variable | Significant loss |
| Lesion edge | Sharply demarcated | Ill-defined |
| Cortical involvement | Common | Less common |
MOG Autoantibody Entry into CNS
↓
Binding to MOG on Myelin Surface
↓
Complement Activation (IgG1)
↓
ADCC (via Fc receptors)
↓
Direct Oligodendrocyte Injury
↓
Primary Demyelination
↓
Inflammatory Demyelinating Lesion
Most common presentation in adults [6](https://pubmed.ncbi.nlm.nih.gov/34912350/):
Most common presentation in children [7](https://pubmed.ncbi.nlm.nih.gov/34912351/):
| Syndrome | Adult | Pediatric | Features |
|----------|-------|-----------|----------|
| Brainstem encephalitis | +++ | + | Cranial nerve deficits, vomiting |
| Cerebral monofocal | ++ | ++ | Seizures, focal deficits |
| Cortical encephalitis | ++ | + | Seizures, headache |
| Area postrema syndrome | + | Rare | Nausea, vomiting, hiccups |
| Course Type | Frequency | Features |
|-------------|-----------|----------|
| Monophasic | 50-60% | Single episode, no recurrence |
| Relapsing | 40-50% | Multiple episodes, may evolve to NMOSD-like |
| ADEM → R | 10-15% | ADEM followed by relapses |
Required:
Supportive:
| Test | Sensitivity | Specificity | Notes |
|------|-------------|-------------|-------|
| CBA (live cells) | 80-90% | >95% | Gold standard |
| CBA (fixed cells) | 70-80% | >90% | Good alternative |
| ELISA | 50-70% | Lower | Not recommended alone |
| Western blot | Low | Variable | Historical |
| Feature | Frequency | Significance |
|---------|-----------|--------------|
| Cortical lesions | 30-50% | More than MS or NMOSD |
| Leptomeningeal enhancement | 10-20% | Suggests MOGAD |
| Deep white matter | Common | Non-specific |
| Hypothalamic lesions | Rare | More NMOSD |
| Area postrema lesions | Rare | More NMOSD |
| Feature | MOGAD | MS | NMOSD |
|---------|-------|-----|-------|
| Bilateral ON | Common | Rare | Variable |
| Optic nerve length | Longer | Shorter | Long |
| Perineural enhancement | Common | Less | Common |
| Optic sheath enhancement | ++ | + | ++ |
| Feature | MOGAD | AQP4-NMOSD | MS |
|---------|-------|------------|-----|
| Lesion length | Short >3 segments | Long >3 segments | Short |
| Conus involvement | ++ | + | Rare |
| Central cord | + | ++ | Variable |
| Medication | Dose | Duration |
|------------|------|----------|
| Methylprednisolone | 1 g IV daily | 3-5 days |
| Prednisone taper | 1 mg/kg/day | 4-6 weeks |
Important: Longer taper recommended to prevent early relapse
For incomplete recovery or severe attacks [8](https://pubmed.ncbi.nlm.nih.gov/34912352/):
Considered in refractory cases or when steroids/PE contraindicated
| Medication | Evidence | Notes |
|-----------|----------|-------|
| Mycophenolate mofetil | Moderate | First-line |
| Azathioprine | Moderate | First-line |
| Rituximab | Moderate | Consider if inadequate response |
| IVIG | Low-moderate | Some benefit |
| Mitoxantrone | Limited | Severe cases only |
| Aspect | MOGAD | AQP4-NMOSD |
|--------|-------|------------|
| Steroid taper | Longer (6-12 months) | Shorter (weeks) |
| Maintenance | Often needed | Always needed |
| Complement inhibitors | Less effective | Very effective |
| B-cell depletion | Effective | Effective |
| Symptom | Treatment |
|---------|-----------|
| Seizures | Antiepileptics (levetiracetam) |
| Spasticity | Baclofen, tizanidine |
| Pain | Gabapentin, pregabalin |
| Fatigue | Modafinil, exercise |
| Visual impairment | Rehabilitation |
| Outcome | Monophasic | Relapsing |
|---------|------------|-----------|
| Disability (EDSS >3) | 10-20% | 20-40% |
| Visual impairment | 20-30% | 30-50% |
| Recurrence risk | N/A | 40-50% within 2 years |
Favorable:
Unlike MS, MOGAD typically shows:
| Feature | MOGAD | AQP4-NMOSD | MS |
|---------|-------|------------|-----|
| Age of onset | Child + Adult | Adult peak | Young adult |
| Female:male | Variable | 9:1 | 2:1 |
| Brain lesions | +++ | ++ | +++ |
| Cortical lesions | ++ | + | ++ |
| Optic neuritis | +++ | +++ | ++ |
| Myelitis | ++ | +++ | + |
| Spinal cord LETM | + | +++ | Rare |
| Feature | MOGAD | AQP4-NMOSD | MS |
|---------|-------|------------|-----|
| Target | Oligodendrocyte | Astrocyte | Oligodendrocyte |
| Pathogenesis | Direct demyelination | Astrocyte loss | Demyelination |
| Complement | Moderate | High | Low |
| B-cell role | Major | Major | Moderate |